News

A biomarker used to detect a rare neurodegenerative disorder of cholesterol metabolism, Niemann-Pick disease type C1 (NPC1), may also be useful for diagnosing another class of rare diseases known as congenital disorders of glycosylation (CDG), suggests a study by researchers at the National Institutes of Health.

Uterine fibroids during pregnancy do not appear to result in undersized newborns, suggests a study by researchers at the National Institutes of Health. The finding allays concerns from previous studies that fibroids might result in smaller-than-normal infants. In fact, the study found that infants born to mothers with fibroids had slightly larger head, arm and thigh circumferences, though not to the extent that they would interfere with birth. The researchers also confirmed prior results suggesting a link between fibroids and increased risk for preterm birth.

In this increasingly digital world, we must strive to better understand how technology and media affect development, health outcomes, and interpersonal relationships from infancy through adolescence. NICHD has a longstanding commitment to research on these topics.

Research conducted at NICHD and at NICHD-funded institutions continues to bring us closer to fulfilling our vision of ensuring healthy pregnancies, healthy children, and healthy and optimal lives.

What defines eating for health? Clearly, there is no one-size-fits-all healthy diet. The emerging field of precision nutrition aims to deliver personalized dietary recommendations to optimize health and quality of life based on an individual’s genetics, gut microbes, and other biological, lifestyle, environmental, and social factors.

Steroid treatment before birth appears to improve survival and reduce complications among extremely preterm infants, according to a study funded by the National Institutes of Health. Antenatal steroid therapy, given to women at risk of preterm delivery, causes the fetal lungs to mature and has been shown to improve survival and reduce complications among infants born from 24 to 34 weeks of pregnancy. However, previous studies of the treatment for infants born between the 22nd and 23rd week—those at greatest risk for death and disability—were inconclusive.

Eight years ago, NIH announced a collaboration with the Bill & Melinda Gates Foundation to develop solutions for a variety of global health challenges. Learn how NICHD research is supporting this goal.

A treatment to move blood from the umbilical cord into an infant’s body may improve the overall health of newborns classified as non-vigorous—limp, pale and with minimal breathing, suggests a study funded by the National Institutes of Health. The procedure, known as umbilical cord milking, involves gently squeezing the cord between the thumb and forefinger and slowly pushing the blood into the abdomen.

Drug labels for diazepam and clindamycin now include better information for healthcare providers on recommended usage and dosage in pediatric populations.

The recent shortage of infant formula underscores its importance for the health of children in the United States, making this an opportune time for Dr. Bianchi to reflect on NICHD’s work to advance infant nutrition research.

Giving the hormone adiponectin to pregnant mice with obesity prevented later life obesity and related health conditions in their offspring, according to a study funded by the National Institutes of Health. The findings suggest that adiponectin, a hormone produced by fat cells, could play a role in reducing the lifelong obesity risk of children born to mothers with obesity during pregnancy.

NICHD-funded small business programs have led to innovations for patients, healthcare providers, researchers, and more. Learn about these success stories.

Researchers have developed a calculator to estimate the risk that cytomegalovirus (CMV) will pass to a fetus during pregnancy. By offering a noninvasive way to predict the chance of congenital CMV based on individual characteristics, this tool may help healthcare providers counsel pregnant people with CMV.

Clinical research networks bring together scientists, clinicians, and community stakeholders to identify important clinical questions and design and conduct high-quality studies to answer them. Scientific evidence generated by such studies can impact clinical care, as several recent findings from NICHD’s networks demonstrate.

Treating newborns at risk for hypoglycemia (low blood sugar) with a preventive oral dose of the sugar dextrose does not appear to increase their overall risk for neurological or sensory impairment at age 2, suggests a study funded by the National Institutes of Health. However, compared to a similar group of at-risk infants treated with a placebo, children treated as infants had a slightly higher risk of motor delay and slightly lower scores on a test of cognitive, language, and motor skills. The authors concluded that the study may not have included enough participants to detect an increased risk for adverse effects. They urged caution in treating infants at risk for hypoglycemia preventively with dextrose gel and called for future evaluations of the study participants later in childhood.

Hydrocortisone is no more effective than placebo at preventing damage that can result from oxygen and ventilator therapy necessary to keep preterm infants alive, according to research funded by the National Institutes of Health. The study of a potential treatment for the condition, known as bronchopulmonary dysplasia, appears in the New England Journal of Medicine.

Children who were first given juice before they were six months old were more likely to have overweight or obesity in early and mid-childhood, compared to kids who were given juice at one year old or later, according to a study by researchers at the National Institutes of Health. The finding provides additional support for a theory that giving young children sweet foods or drinks may foster a preference for sweet tastes that can lead to weight gain later in childhood.

Vaccinating women against SARS-CoV-2 in mid to late pregnancy could provide their infants at least some protection against COVID-19 through six months of age, suggests a small study funded by the National Institutes of Health. Compared to infants born to mothers who had COVID-19 during pregnancy, infants born to vaccinated mothers were much more likely to have antibodies against the virus.

On average, scores on development tests were lower for infants born earlier in the range of a term pregnancy—from 37 to 41 weeks—than for those born later in the range, suggests a study by researchers at the National Institutes of Health. The slight difference in scores, first apparent at eight months, persisted through age seven. The findings may have implications for current practice guidelines recommending induction of labor for non-medical reasons at the 39th week of pregnancy.

Small NIH study contributes to understanding of COVID-19 during pregnancy.